# Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

> **NCT00307736** · PHASE1,PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 32 (actual)

## Conditions studied

- Rectal Cancer
- Adenocarcinoma of the Rectum

## Interventions

- **DRUG:** 5-fluorouracil
- **DRUG:** bevacizumab
- **DRUG:** erlotinib
- **PROCEDURE:** External beam radiation therapy (EBRT)

## Key facts

- **NCT ID:** NCT00307736
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-04
- **Final completion:** 2011-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-05-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00307736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00307736, "Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00307736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*